As a matter of facts, this drug, whose efficacy in the treatment of liver metastases has been established [26], is an antibody against vascular endothelial growth factor and so the difference in the fp before and after therapy may reflect the changes of tumor microenvironment during chemotherapy. Here, VEGFA is linked to neoplasm.